Rapid Therapeutic Science Laboratories, Inc.
RTSL
$0.0074
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 100.00 | 200.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 100.00 | 200.00 |
| Cost of Revenue | -- | -- | -- | 0.00 | 0.00 |
| Gross Profit | -- | -- | -- | 100.00 | 200.00 |
| SG&A Expenses | 566.10K | 590.80K | 1.28M | 1.87M | 2.02M |
| Depreciation & Amortization | -18.50K | -18.50K | -18.50K | 44.80K | 23.00K |
| Other Operating Expenses | -82.50K | -- | -- | -- | -- |
| Total Operating Expenses | 465.10K | 572.30K | 1.26M | 1.92M | 2.04M |
| Operating Income | -465.10K | -572.30K | -1.26M | -1.92M | -2.04M |
| Income Before Tax | 59.50K | -23.70K | -1.79M | -3.06M | -3.41M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 0.06 | -0.02 | -1.79 | -3.06 | -3.41 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 59.50K | -23.70K | -1.79M | -3.06M | -3.41M |
| EBIT | -465.10K | -572.30K | -1.26M | -1.92M | -2.04M |
| EBITDA | -441.10K | -548.30K | -1.24M | -1.89M | -2.02M |
| EPS Basic | 0.01 | 0.00 | -0.23 | -0.39 | -0.44 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.14 | -0.25 | -0.28 |
| EPS Diluted | 0.01 | 0.00 | -0.23 | -0.39 | -0.44 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.14 | -0.25 | -0.28 |
| Average Basic Shares Outstanding | 31.79M | 31.22M | 30.99M | 30.99M | 30.98M |
| Average Diluted Shares Outstanding | 31.79M | 31.22M | 30.99M | 30.99M | 30.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |